Microbot Medical and Corewell Health collaborate on LIBERTY® robotic system for telerobotic cardiovascular procedures, presenting research at CRT 2025.
Quiver AI Summary
Microbot Medical Inc. has announced a significant milestone in its collaboration with Corewell Health to advance robotic telesurgery for endovascular applications, specifically the LIBERTY® Endovascular Robotic System. Led by Dr. Ryan Madder, the project is evaluating the feasibility of using LIBERTY® for simulated cardiovascular procedures at two Corewell Health sites. This research has been accepted for presentation at the upcoming Cardiovascular Research Technologies annual meeting and will be published in the Journal of the American College of Cardiology. Dr. Madder commented on the positive performance of the LIBERTY® system in a telerobotic setting, highlighting its potential in healthcare. Harel Gadot, CEO of Microbot Medical, expressed excitement about the project's prospects for enhancing access to high-quality healthcare. The telesurgery feature of LIBERTY® is still in development and not yet submitted for FDA approval.
Potential Positives
- Collaboration with Corewell Health™ marks a significant milestone in advancing robotic telesurgery, indicating strong partnerships in the healthcare sector.
- The LIBERTY® system's feasibility for telerobotic applications is being presented at a prominent cardiovascular research conference, enhancing the company's visibility and credibility in the medical community.
- The research's acceptance for publication in the Journal of the American College of Cardiology (JACC) reflects the potential impact and innovation of Microbot's technology.
- Comments from Dr. Madder and CEO Harel Gadot highlight the transformative potential of the LIBERTY® system, positioning it as a solution to improve healthcare access, especially in remote areas.
Potential Negatives
- The telesurgery feature of LIBERTY® is still under development and is not covered under its pending 510(k) premarket submission with the U.S. Food and Drug Administration, indicating potential regulatory setbacks.
- The company explicitly states that further development and commercialization depend on additional working capital, which raises concerns about financial stability.
- The acknowledgment of risks, including uncertainty in regulatory approvals and market conditions, highlights vulnerabilities in their strategic plans for the LIBERTY® system.
FAQ
What is the LIBERTY® Endovascular Robotic System?
The LIBERTY® system is an innovative, single-use, fully disposable endovascular robotic system developed by Microbot Medical.
What is the collaboration between Microbot Medical and Corewell Health™?
They are collaborating to advance robotic telesurgery for endovascular applications, assessing the feasibility of using LIBERTY® for cardiovascular procedures.
Where will the research be presented?
The research will be presented at the Cardiovascular Research Technologies (CRT) annual meeting in Washington D.C. from March 8-11, 2025.
Who is leading the project at Corewell Health™?
The project is led by Ryan Madder, M.D., Section Chief of Interventional Cardiology at Corewell Health™.
Is the telesurgery feature of LIBERTY® currently available?
No, the telesurgery feature is still under development and is not covered under the pending FDA submission.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MBOT Hedge Fund Activity
We have seen 15 institutional investors add shares of $MBOT stock to their portfolio, and 14 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC added 105,658 shares (+inf%) to their portfolio in Q4 2024, for an estimated $118,336
- ALPHACENTRIC ADVISORS LLC removed 60,000 shares (-60.0%) from their portfolio in Q4 2024, for an estimated $67,200
- UBS GROUP AG removed 43,429 shares (-97.6%) from their portfolio in Q4 2024, for an estimated $48,640
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 29,728 shares (+inf%) to their portfolio in Q4 2024, for an estimated $33,295
- VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC removed 15,494 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $13,851
- VIRTU FINANCIAL LLC removed 13,379 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $11,960
- SCOTIA CAPITAL INC. added 13,275 shares (+inf%) to their portfolio in Q4 2024, for an estimated $14,868
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY
®
Endovascular Robotic System, today announced its collaboration with Corewell Health™ has reached another meaningful milestone. Under a collaboration agreement, Microbot Medical
®
and Corewell Health™ are working together to advance robotic telesurgery for endovascular applications. Led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health™ in Grand Rapids, Michigan, the project assesses the feasibility of using LIBERTY
®
to perform simulated cardiovascular interventional procedures across two sites within the Corewell Health™ system located 5 miles apart. The research has been accepted for presentation at the Cardiovascular Research Technologies (CRT) annual meeting, being held from March 8-11, 2025, in Washington D.C., and will be published in the Journal of the American College of Cardiology (JACC) Interventions online edition.
Abstract/Presentation Title
: Feasibility of Telerobotic Coronary Artery Wiring Using A Novel Miniaturized Robotic System: A Pre-clinical Ex Vivo Study
Presenter:
Trisha Gomez, MD
Presentation Date/Time
: Monday, March 10, 2025, 4:12-4:20pm ET.
Location:
Theater #4
“In this study, the LIBERTY
®
robotic system functioned well in a telerobotic setting. The system’s small footprint and disposable design create a multitude of exciting possibilities for future telerobotic endovascular procedures,” commented Dr. Madder.
“We’re excited that this groundbreaking research, led by Dr. Madder and the Corewell Health team, has been selected for presentation, which we believe reflects the importance of integrating telesurgery in the future of healthcare,” commented Harel Gadot, Chairman, CEO and President. “Incorporating telesurgery capabilities is an important part of our long-term strategy for LIBERTY
®
, and we are pleased to demonstrate its feasibility. We believe that robotic telesurgery will increase access to high quality healthcare for patients in remote locations in the US and around the world.”
Cardiovascular Research Technologies (CRT) is a leading educational forum on new cardiovascular technology and procedures for physicians and health-care professionals. CRT provides a forum for exemplary education for interventional cardiologists, general cardiologists, cardiothoracic and vascular surgeons, catheterization laboratory managers, nurses and technologists, scientists and those with an interest in cardiovascular medicine.
The telesurgery feature of LIBERTY
®
is still under development at Microbot and is not covered under its pending 510(k) premarket submission with the U.S. Food and Drug Administration.
About Microbot Medical
®
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical
®
is available at
http://www.microbotmedical.com
.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY
®
Endovascular Robotic System, including its potential telesurgery feature, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY
®
Endovascular Robotic System in the United States, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical
®
can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical
®
disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact:
IR@microbotmedical.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
